Tuhura biosciences discovery research on targeting the delta opioid receptor (dor) to reprogram myeloid-derived suppressor cells (mdscs) selected for oral presentation at the 67th ash annual meeting and exposition

Oral presentation highlights the first time it's been demonstrated that the dor is expressed on tumor-associated mdscs, and that dor inhibition reprograms multiple mechanisms of mdsc- induced immunosuppression representing a new target in overcoming acquired resistance to cancer immunotherapy the first demonstration that dor is expressed on tumor-associated macrophages (tams), with dor inhibition modulating their immunosuppressive capabilities presentation from the moffitt cancer center in collaboration with tuhura scientists demonstrating the presence of the dor on mdscs from patients with myeloid dysplastic syndrome (mds) and restoration of stem cell proliferation with dor inhibition tampa, fla. , nov. 3, 2025 /prnewswire/ -- tuhura biosciences, inc. (nasdaq: hura) ("tuhura"), a phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its research on the potential role of the delta opioid receptor in controlling the immunosuppressive capabilities of mdscs was accepted for an oral presentation at the 67th american society of hematology (ash) annual meeting and exposition taking place in orlando, fl from december 6-9, 2025.
ASH Ratings Summary
ASH Quant Ranking